LogicBio's market value halves after FDA clinical hold

3 February 2022
logicbio_large

Genetic medicine company LogicBio Therapeutics (Nasdaq: LOGC) lost 55% of its stock market value on Wednesday.

The US company had earlier provided an update on the LB-001 clinical development program, namely that the US Food and Drug Administration (FDA) has told LogicBio that its Phase I/II SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia has been placed on clinical hold.

No problem with earlier patients

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology